Landiolol for rate control in decompensated heart failure due to atrial fibrillation: the LARISA trial
In AHF with reduced LVEF, protocolized landiolol-based intensive rate control provides faster and safe HR reduction with early symptomatic benefit compared with standard therapy.
Authors
- Ales Benak
- Marek Šramko (ORCID: https://orcid.org/0000-0002-1379-0086)
- Martin Kleissner (ORCID: https://orcid.org/0000-0003-0262-9673)
- Jakub Toman (ORCID: https://orcid.org/0000-0002-7396-5503)
- Michal Pazdernik
- Josef Kautzner
Institutions
- Institute of Clinical and Experimental Medicine (CZ)
- General University Hospital in Prague (CZ)
Publication Details
- Journal
- European Heart Journal Acute Cardiovascular Care
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1093/ehjacc/zuag027
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00